

## Ascletis Pharma Inc.

## 歌禮製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1672)

10 April 2024

Dear registered shareholder(s),

## **Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Ascletis Pharma Inc. (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.ascletis.com and the HKEXnews website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications<sup>(Note)</sup>, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form in the future.

If you want to receive future Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Share Registrar or send an email to ascletis.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

By order of the Board Ascletis Pharma Inc. Jinzi Jason WU Chairman

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

## 以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07 條,歌禮製藥有限公司(「**公司**」)謹此通知 閣下,公司已採用以電子方式發布公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b) 中期報告及其中期報告摘要(如適用); (c) 會議通知; (d) 上市文件; (e) 通函和 (f) 委任表格。

請注意,所有日後公司通訊的英文版和中文版將在公司網站 www.ascletis.com 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊<sup>(欄)</sup>,公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者, 閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前,本公司未來將以印刷本形式發送可供採取行動的公司通訊( $^{
m Mil}$ )。

若 閣下希望收取日後公司通訊之印刷本,請填妥本函背頁之回條並交回股份過戶處,或發送電子郵件至 ascletis.ecom@computershare.com.hk, 並註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。 請注意,收取日後公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)期間致電股份過戶處(852)28628688 查詢。

承董事會命 **歌禮製藥有限公司** *主席* **吳勁梓** 

2024年4月10日

附註:可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

REPLY FORM 回條					
( <b>T</b> 17	omputershare Hong Kong Investor Services Lin 'he "Share Registrar") 'M Floor, Hopewell Centre 33 Queen's Road East, Wanchai, Hong Kong	nited	②: 香港中央證券₹ (「股份過戶處 香港灣仔皇后才 合和中心 17M 秒	」 <b>)</b> <道東 183 號	
	noose ONLY ONE of the options below) 医選項中只選擇其中一項				
Optio	on 1: Provide your email address Communications (Note 3) of the your personalized QR code	-	issemination by so	rporate canning	onalized <b>QR</b> Code 專屬二維碼
	 發佈可供採取行動的未來公司	通訊 <sup>(附註 3)</sup>			
	You are <b>NOT required</b> to ret 如選擇了選項 1 · 閣下無	turn this Reply Form if you 真交回本回條。	u choose Option	1.	
Option 選項 2	1 2: I/we hereby provide my/our email address company (the "Company") via electronic care 本人/吾等現以書面提供本人/吾等之的電子	lissemination			
Name o	 of Securities holder(s) 證券持有人姓名:	Name of the listed of	company 上市公司名稱	:	
		Ascletis Ph 歌禮製藥拜			
Email a	ddress 電郵地址: (Notes 3 / 附註 3)				
Option	3: I/we hereby request for receipt of future C	Corporate Communications* in prin	nted form and noted th	at this instruction is valid	l only for one year starting
選項3	from the receipt date of instruction. (Notes 5	(Please mark "✓" in the below box	if applicable)		
E	nglish Version 英文版本	Chinese Version 中文版本		English and Chinese	Version 英文及中文版本
Signatur 簽名:	re(s): <sup>(Notes 1)</sup> 附註 1)	Contact number: 聯絡電話號碼:		Date: 日期:	

Notes M#:

Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid. 請清楚填安 閣下之所有資料。如屬聯名股東·則本回條須由所有聯名股東聯合簽署·方為有效。

- 語の基本系 画 | え)ロステザ 外側側型など、アルロボルロリアの主義を受けます。 Any Reply Form with no signature or otherwise incorrectly completed will be void. 任何回線表示有線量を注意形面線系元回線。 別本回線系統作義 If the Company does not receive a functional email address in your reply, the Company will send the Actionable Corporate Communication in printed form in the future. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holders wish is exercise their rights or make an election as the issuer's securities holders with the exercise their rights or make an election as the issuer's securities holders with the exercise their rights or make an election as the issuer's securities holders with their rights or make an election as the issuer's securities holders.

  如公司选择收到 圖下的有效電子郵件地址,本公司將以印刷本形式發送可供採取行動的未來公司通訊。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示具擬如何行使具有關 證券持有人的權利 的公司通訊。
- 的公立細語。 財 you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered. 如 閣下通過二維碼。電影、回線及/威其他方式提供多於一個的電子器件地址、只有、閣下最後提供的電子器件地址結審被用於登記。 If you mark "" in the box in Option 3, no email address will be registered and only Corporate Communications" in printed form will be received. 如 閣下在選項 3 方格內劃上 "》」號,將不會有電子郵件地址被登記,只有公司通訊。的印刷版會被收取。

- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form 為免存髮·在本回條上的任何額外指示·公司將不予處理。
- Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim eport, notice of meeting, circular and proxy form. 除来另有注册,公司通讯分指公司已要也被养予发出这些未予发出这样美工的。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- (iii)
- SONAL INFORMATION COLLECTION STATEMENT 收集個人資料限明
  "Personal Data" in this statement has the same meaning as "personal data" in the Personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"),
  本費用中所語的「個人資料」與香港法例第 486 章 (個人資料(杨惠)條例)(「私職條例)」,中「個人資料」的遊養相同。
  "Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.
  國下於本回條所提供的風戶資料新用於(包括任果於)有關公司以電子方式發布公司通訊及款 國下持有的公司服务有關的其他事宜上與 國下縣格。國下是目顧向本公司提供個人資料。若 國下未能是供足夠資料、本公司可能無法處理 國下在本回條上所述的指示及减要求。
  "Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
  公司司就任何所說明的用途或社法例规定的情况下,將 個下的個人資料按賽或轉移給公司的附屬公司、股份過戶處、及/或其他公司或團體・並將在擔當期間保留該等個人資料作核實及紀錄用途。
  "You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong PrivacyOfficer of the Share Registrar at 17M. Floor, Hopewell Certure, 183 Queen's Road East, Wanchai, Hong Kong or by email at PrivacyOfficer of the Khare Registrar at 17M. Floor, Hopewell Certure, 183 Queen's Road East, Wanchai, Hong Kong or by email at PrivacyOfficer of the Road East, Wanchai, Hong Kong or by email at PrivacyOfficer of the Khare Registrary of the Market Computershare com his.

  圖 下海經報 在機能 不過度的 中華 Advanced Computershare com his. PrivacyOfficer@cor

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼: 37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us. No postage is necessary if posted in Hong Kong.

當 閣下寄回此回條時·請將郵寄標籤剪貼於信封上 如在本港投寄· 閣下無需支付郵費或貼上郵票。